Emblaveo is a drug owned by Abbvie Inc. It is protected by 7 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 07, 2033. Details of Emblaveo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9695122 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(7 years from now) | Active |
| US8969566 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(7 years from now) | Active |
| US9284314 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(7 years from now) | Active |
| US8471025 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(6 years from now) | Active |
| US7112592 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(8 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8835455 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(5 years from now) | Active |
| US7612087 | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(1 year, 6 months from now) | Active |
FDA has granted several exclusivities to Emblaveo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Emblaveo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Emblaveo.
Exclusivity Information
Emblaveo holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2033. Details of Emblaveo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 07, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 07, 2033 |
Several oppositions have been filed on Emblaveo's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Emblaveo's generic, the next section provides detailed information on ongoing and past EP oppositions related to Emblaveo patents.
Emblaveo's Oppositions Filed in EPO
Emblaveo has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 26, 2019, by Lederer & Keller Patentanwälte Partnerschaft Mbb. This opposition was filed on patent number EP17182561A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17182561A | Nov, 2019 | Lederer & Keller Patentanwälte Partnerschaft mbB | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Emblaveo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Emblaveo's family patents as well as insights into ongoing legal events on those patents.
Emblaveo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Emblaveo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 07, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Emblaveo Generics:
There are no approved generic versions for Emblaveo as of now.
About Emblaveo
Emblaveo is a drug owned by Abbvie Inc. Emblaveo uses Avibactam Sodium; Aztreonam as an active ingredient. Emblaveo was launched by Abbvie in 2025.
Approval Date:
Emblaveo was approved by FDA for market use on 07 February, 2025.
Active Ingredient:
Emblaveo uses Avibactam Sodium; Aztreonam as the active ingredient. Check out other Drugs and Companies using Avibactam Sodium; Aztreonam ingredient
Dosage:
Emblaveo is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.5GM BASE/VIAL;1.5GM/VIAL | POWDER | Prescription | INTRAVENOUS |